G9097 HCPCS Reimbursement & Policy Benchmarks

HCPCS Level II code G9097 documents the initial disease-status classification for esophageal cancer limited to adenocarcinoma or squamous cell carcinoma, specifically where the tumor is staged as t4, any n, m0 with no progression, recurrence, or metastases. The code is designated for use within a Medicare-approved demonstration project and reflects an oncology staging determination performed prior to neo-adjuvant therapy, if any. Nationally, accurate staging codes like G9097 support care coordination, clinical trial eligibility assessment, and demonstration project reporting.

Key payers in the scope of this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent and service context, guidance on where the service is typically delivered, and a summary of common modifiers and administrative considerations where available. The publication also highlights the clinical context for staging esophageal adenocarcinoma and squamous cell carcinoma at the t4, any n, m0 classification and the implications for care pathways and demonstration-project reporting.

Data not available in the input is noted where payer-specific policies, associated taxonomies, ICD-10 diagnoses, related codes, and service-line details were not provided.

Billing Code Overview

HCPCS Level II code G9097 describes an oncology disease-status determination for esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as the predominant cell type. The code specifies that the extent of disease is initially established as t4, any n, m0 prior to any neo-adjuvant therapy (if given) and that there is no evidence of disease progression, recurrence, or metastases. This coding statement is intended for use in a Medicare-approved demonstration project.

Service type: Oncology disease-status assessment, initial staging classification

Typical site of service: Hospital outpatient oncology clinic or specialized cancer center

Clinical Context

A 64-year-old male with a newly diagnosed distal esophageal adenocarcinoma undergoes staging and multidisciplinary evaluation prior to neoadjuvant therapy. Imaging (contrast-enhanced chest/abdomen CT and PET-CT) and endoscopic ultrasound establish tumor extent as T4, any N, M0 with no evidence of distant metastasis or interval progression. The oncology team documents disease status for a Medicare-approved demonstration project using billing code G9097. Typical workflow: initial diagnosis by gastroenterology with endoscopic biopsy, staging by radiology and endoscopic ultrasound, multidisciplinary tumor board review, documentation of baseline T4, N, M0 status in the oncology record prior to initiation of neoadjuvant chemoradiation, and submission of the demonstration-project-specific code G9097 for the disease-status reporting visit. Typical site of service is an outpatient oncology clinic or hospital outpatient department during a pre-treatment staging visit. Common patient presentation includes dysphagia, weight loss, and biopsy-confirmed adenocarcinoma or squamous cell carcinoma with local invasion (T4) but no distant metastasis.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no modifier applies to the service.

Taxonomy Code	Specialty	Notes
`2085R0200X`	Surgical Oncology	Surgeons who perform esophagectomy and staging procedures.
`208600000X`	Medical Oncology	Oncologists who manage neoadjuvant therapy and document baseline disease status.
`2084P0800X`	Radiation Oncology	Radiation oncologists involved in neoadjuvant planning and staging interpretation.
`207K00000X`	Gastroenterology	Gastroenterologists who perform diagnostic endoscopy and biopsies relevant to staging.
`208000000X`	General Surgery	Surgeons who participate in staging and operative planning.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C15.9`	Malignant neoplasm of esophagus, unspecified	General code for esophageal cancer when site detail is unspecified; relevant for reporting disease status.
`C15.0`	Malignant neoplasm of cervical esophagus	Esophageal cancer location that may alter staging and treatment planning for the disease-status assessment.
`C15.2`	Malignant neoplasm of thoracic esophagus	Common location for adenocarcinoma or squamous cell carcinoma requiring T4 assessment.
`C15.4`	Malignant neoplasm of lower third of esophagus	Distal esophageal tumors often managed with neoadjuvant therapy; relevant to `G9097` documentation.
`C15.8`	Malignant neoplasm of overlapping sites of esophagus	Used when tumor spans multiple esophageal subsites; impacts staging documentation.
`Z85.028`	Personal history of malignant neoplasm of other digestive organs and peritoneum	May appear in problem lists for prior cancers; influences surveillance and staging context.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`43235`	Upper gastrointestinal endoscopy with biopsy, single or multiple	Diagnostic endoscopy to obtain tissue for histologic confirmation before disease-status documentation.
`43247`	Upper GI endoscopy with dilation, with other procedures as indicated	May be performed for palliation or to permit staging procedures prior to documenting disease status.
`76977`	Ultrasound guidance for needle placement (e.g., biopsy)	Used when image guidance is required for staging biopsies or sampling regional nodes.
`43259`	Endoscopy, esophagus, rigid or flexible; with dilation	Alternative endoscopic procedure performed during initial evaluation and staging.
`76998`	Unlisted ultrasound procedure	Rarely used for specialized imaging during staging when no specific CPT exists.

OpenPayer

Summary & Overview

HCPCS G9097: Esophageal Cancer Initial Disease-Status (t4, any n, m0)